Incidence, prevalence and mortality of chronic liver diseases in Sweden between 2005 and 2019
暂无分享,去创建一个
J. Ludvigsson | N. Ndegwa | H. Hagström | P. Nasr | E. von Seth | R. Mayerhofer | Raphaela Mayerhofer
[1] A. Duberg,et al. Monitoring the progress towards the elimination of hepatitis B and C in Sweden: estimation of core indicators for 2015 and 2018 , 2022, BMC Infectious Diseases.
[2] M. Ekstedt,et al. Low awareness of non-alcoholic fatty liver disease in patients with type 2 diabetes in Swedish Primary Health Care , 2021, Scandinavian journal of gastroenterology.
[3] H. El‐Serag,et al. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention , 2020, Nature Reviews Gastroenterology & Hepatology.
[4] J. Jia,et al. Regional variation and temporal trend of primary biliary cholangitis epidemiology: A systematic review and meta‐analysis , 2020, Journal of gastroenterology and hepatology.
[5] E. Tapper,et al. Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[6] J. Ludvigsson,et al. Validity of administrative codes associated with cirrhosis in Sweden , 2020, Scandinavian journal of gastroenterology.
[7] J. Ngu,et al. Trends in Incidence of Autoimmune Liver Diseases and Increasing Incidence of Autoimmune Hepatitis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[8] Z. Younossi,et al. Changes in the Global Burden of Chronic Liver Diseases From 2012 to 2017: The Growing Impact of NAFLD , 2020, Hepatology.
[9] A. Singal,et al. Trends in Liver Disease Etiology Among Adults Awaiting Liver Transplantation in the United States, 2014-2019. , 2020, JAMA network open.
[10] E. Björnsson,et al. Increased incidence of autoimmune hepatitis is associated with wider use of biological drugs , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[11] Z. Younossi,et al. The Global Epidemiology of NAFLD and NASH in Patients with type 2 diabetes: A Systematic Review and Meta-analysis. , 2019, Journal of hepatology.
[12] N. Björkström,et al. Characteristics and outcome of hepatocellular carcinoma in patients with NAFLD without cirrhosis , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[13] N. Sattar,et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts , 2019, BMC Medicine.
[14] V. Wong,et al. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[15] P. Kamath,et al. Burden of liver diseases in the world. , 2019, Journal of hepatology.
[16] J. Lazarus,et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. , 2018, Journal of hepatology.
[17] P. Marcellin,et al. Liver diseases: A major, neglected global public health problem requiring urgent actions and large‐scale screening , 2018, Liver international : official journal of the International Association for the Study of the Liver.
[18] M. Ekstedt,et al. Natural History of NAFLD/NASH , 2017, Current Hepatology Reports.
[19] Alan D. Lopez,et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.
[20] J. Ludvigsson,et al. The Swedish cause of death register , 2017, European Journal of Epidemiology.
[21] A. Törner,et al. The underreporting of hepatocellular carcinoma to the cancer register and a log‐linear model to estimate a more correct incidence , 2017, Hepatology.
[22] Robert Blissett,et al. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe , 2016, Hepatology.
[23] L. Henry,et al. Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.
[24] S. Lindgren,et al. Incidence, clinical presentation and mortality of liver cirrhosis in Southern Sweden: a 10‐year population‐based study , 2016, Alimentary pharmacology & therapeutics.
[25] Mohsen Naghavi,et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis , 2014, BMC Medicine.
[26] H. Vilstrup,et al. Autoimmune hepatitis in Denmark: incidence, prevalence, prognosis, and causes of death. A nationwide registry-based cohort study. , 2014, Journal of hepatology.
[27] J. Ludvigsson,et al. External review and validation of the Swedish national inpatient register , 2011, BMC public health.
[28] J. Ludvigsson,et al. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research , 2009, European Journal of Epidemiology.
[29] L. Holmberg,et al. The completeness of the Swedish Cancer Register – a sample survey for year 1998 , 2009, Acta oncologica.
[30] L. Henry,et al. NAFLD AND NASH: Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention , 2018 .